Barnes & Noble Education, Inc. september 8, 2025 Please complete the form below to contact Kaplan Fox regarding the Barnes & Noble Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox is Investigating Barnes & Noble Education, Inc. (BNED) for Potential Securities Law Violations Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Barnes & Noble Education, Inc. (“Barnes & Noble” or the “Company”) (NYSE: BNED). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Barnes & Noble investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. On July 18, 2025, after markets closed, Barnes & Noble disclosed in a filing with the U.S. Securities and Exchange Commission that its annual report for the fiscal year ended May 3, 2025 will be delayed and that the Audit Committee of the Board of Directors had commenced an internal investigation with the assistance of outside counsel and advisors. Further, the Company disclosed that the internal investigation was initiated after “certain information regarding the recording of cost of digital sales was brought to the attention of management in July 2025.” The Company further stated that “based on initial findings, which could change as the investigation is in its early stages, management believes that the Company may have a potential overstatement of up to $23.0 million in the aggregate to its accounts receivable balance as of its May 3, 2025 fiscal year-end” and that “the Company expects to report at least one material weakness related to the appropriate review and approval of manual journal entries. . . .” Following this news, the price of Barnes & Noble stock declined $2.36 per share, or 21%, to close at $8.87 per share on July 21, 2025. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT:Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003pmayer@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Barnes & Noble Education, Inc. See the Case Dow, Inc. See the Case Semler Scientific, Inc. See the Case LifeMD, Inc. See the Case C3.ai, Inc. See the Case Snap, Inc. See the Case KinderCare Learning Companies, Inc. See the Case SelectQuote, Inc. See the Case Unicycive Therapeutics, Inc. See the Case Fiserv, Inc. See the Case Simulations Plus, Inc. See the Case Inspire Medical Systems, Inc. See the Case
